Core Insights - Anteris Technologies reported significant advancements in 2025, focusing on the development of the DurAVR transcatheter heart valve (THV) and positioning itself for leadership in the structural heart market [3][4]. Financial Performance - The company's net operating cash outflows for 2025 were $77.8 million, reflecting increased clinical, regulatory, and manufacturing requirements to support the PARADIGM Trial [4]. - Research and Development (R&D) expenses totaled $69.1 million, which included costs for manufacturing upscaling, clinical trial preparations, and an increase in R&D personnel [6]. - Selling, general, and administrative expenses were reported at $26.1 million [6]. Clinical Developments - Anteris initiated the global pivotal PARADIGM Trial, building on prior experience treating 130 patients with the DurAVR THV, including complex cases [5]. - The company received FDA Investigational Device Exemption (IDE) approval in Q4 2025 to commence the PARADIGM Trial in the U.S. [5]. - The PARADIGM Trial aims to enroll approximately 1,000 patients to evaluate the safety and effectiveness of the DurAVR THV compared to existing transcatheter aortic valve replacements (TAVRs) [8]. Strategic Initiatives - Anteris completed capital raises totaling $320 million in early 2026, including a strategic investment from Medtronic to support the PARADIGM Trial and advance global commercialization of the DurAVR THV System [5]. - The company strengthened its operational infrastructure and advanced its quality management system, achieving ISO 13485 certification for DurAVR THV production [5]. Product Overview - The DurAVR THV is designed to treat aortic stenosis and is the first biomimetic valve, aiming to replicate the performance of a healthy human aortic valve [11]. - The valve is made from Anteris' patented ADAPT tissue, which has been clinically used for over 10 years and is FDA-cleared [11].
Anteris Reports 2025 Financial Results and Provides Corporate Update